Recombinant Human FDFT1 Protein，His

FDFT1, or Farnesyl-diphosphate farnesyltransferase 1, is an enzyme involved in the mevalonate pathway, which is crucial for the biosynthesis of sterols and isoprenoids in eukaryotic cells. Its primary function is to catalyze the transfer of farnesyl groups to proteins, a process known as protein farnesylation, which is essential for the proper localization, function, and stability of various signaling proteins, particularly in the Ras oncogene family. Mutations or dysregulation of FDFT1 can lead to numerous diseases, including various types of cancer and metabolic disorders. Recent studies have focused on the potential of FDFT1 as a therapeutic target, especially in cancer treatment, given its involvement in cell proliferation and survival pathways. Researchers are increasingly interested in characterizing the structure and function of recombinant FDFT1, utilizing techniques such as protein engineering and crystallography, to elucidate its mechanisms of action and interactions with other biomolecules. This knowledge may lead to the development of specific inhibitors that could provide novel therapeutic strategies for diseases linked to FDFT1. Furthermore, understanding the enzyme's role in lipid metabolism has broader implications in studying metabolic syndromes and cardiovascular diseases. As such, ongoing research into FDFT1 and its recombinant forms is critical for advancing our understanding of enzyme regulation, protein synthesis, and the development of targeted therapies.